Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
204 participants
INTERVENTIONAL
2024-08-28
2026-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
block group
* Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3, post-tetanic count \> 1)
* Rocuronium (intravenous, 1.0 mg/kg)
moderate to deep neuromuscular blockade
* Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count \> 1)
* Rocuronium (intravenous, 1.0 mg/kg at induction period)
control group
* Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count \< 0.9)
* Rocuronium (intravenous, 0.3 mg/kg)
shallow to minimal neuromuscular blockade
* Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count \< 0.9)
* Rocuronium (intravenous, 0.3 mg/kg at induction period)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
moderate to deep neuromuscular blockade
* Maintaining moderate to deep neuromuscular blockade during an intraoperative period (Train-of-four 0-3 count, post-tetanic count \> 1)
* Rocuronium (intravenous, 1.0 mg/kg at induction period)
shallow to minimal neuromuscular blockade
* Maintaining shallow to minimal neuromuscular blockade during an intraoperative period (Train-of-four 4, post-tetanic count \< 0.9)
* Rocuronium (intravenous, 0.3 mg/kg at induction period)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with preoperative electrocardiograms showing conduction disturbances
* Patients with neuromuscular disease
* Any other patient who, in the opinion of the investigator, is not a good candidate for the study.
3 Years
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Seoul National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young-Eun Jang
Clinical Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-2303-079-1412
Identifier Type: -
Identifier Source: org_study_id